Clinical Trial Update: An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol [Phase 2]

View source ↗

Summary

Phase 2 extension trial update for inclisiran in participants with cardiovascular disease and high cholesterol; study completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Symptomatic Atherosclerosis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2023-03-24